|
Heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
Galectin-3 (Gal-3), a β-galactoside-binding lectin, plays an important role in inflammation, fibrosis, and heart failure.
|
23117656 |
2013 |
|
Heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
Galectin-3 is a new and promising biomarker for heart failure and myocardial fibrosis.
|
23723328 |
2014 |
|
Heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
Galectin-3, a β-galactoside binding lectin, has been described as a mediator of cardiac fibrosis in experimental studies and as a risk factor associated with cardiovascular events in subjects with heart failure.
|
26312551 |
2015 |
|
Heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
Galectin-3 (Gal-3) is a β-galactoside-binding lectin, which is important in inflammation, fibrosis and heart failure.
|
27959409 |
2017 |
|
Heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
Galectin-3, a novel binding-lectin involved in inflammation and fibrosis, is elevated in heart failure and is independently predictive of mortality in this condition.
|
28242288 |
2017 |
|
Heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
Galectin-3 (Gal-3), indicating cardiac fibrosis, is a documented biomarker of prognosis in HF.
|
28318874 |
2017 |
|
Heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
Galectin-3 (Gal-3) has been linked to cardiac remodeling and poor prognosis in heart failure of different etiologies.
|
28322201 |
2017 |
|
Heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
Galectin-3 (Gal-3), a β-galactoside-binding lectin, has been implicated in myocardial fibrosis, development of left ventricular (LV) dysfunction and transition from compensated LV hypertrophy to overt heart failure (HF), being a novel prognostic marker in HF.
|
28468272 |
2017 |
|
Heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
Galectin-3 (Gal-3) is an important mediator of cardiac fibrosis, particularly in heart failure.
|
28525549 |
2018 |
|
Heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
Galectin-3 (Gal-3) is known as a key fibroblasts activating factor which is involved in the fibrogenesis of several diseases, such as pulmonary fibrosis, vascular fibrosis, and heart failure.
|
28826890 |
2017 |
|
Heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
Galectin-3 and the Mineralocorticoid Receptor Antagonist Canrenone in Mild Heart Failure.
|
28855452 |
2017 |
|
Heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
Galectin-3 is an emerging biomarker for risk stratification in patients with heart failure.
|
28942393 |
2018 |
|
Heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
Galectin-3 (Gal-3) is an independent predictor of poor outcomes and mortality in patients with heart failure (HF).
|
29180917 |
2017 |
|
Heart failure
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Galectin-3 overexpression and secretion is associated with several diseases and is extensively studied in the context of fibrosis, heart failure, atherosclerosis and diabetes mellitus.
|
29344292 |
2018 |
|
Heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
Galectin-3 has been implicated in cardiac and renal fibrosis and serves as a prognostic clinical indicator in heart failure.
|
29417184 |
2018 |
|
Heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
Galectin-3 (Gal-3) and soluble suppression of tumorigenicity 2 (sST2) are the only novel HF biomarkers that are included in the ACC/AHA HF guidelines, but their clinical utility still needs to be demonstrated.
|
29663841 |
2018 |
|
Heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
Galectin-3 (Gal-3) is a mediator of profibrotic pathways and is associated with an increased incidence of heart failure.
|
29861319 |
2019 |
|
Heart failure
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Galectin-3 (Gal-3) and suppression of tumorigenicity 2 (ST2) induce fibrotic alterations in severe MR and heart failure.
|
29896861 |
2018 |
|
Heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
Galectin-3 (GAL-3), a beta galactoside binding lectin, is closely associated with myocardial infarction (MI), myocardial fibrosis and heart failure.
|
30355930 |
2018 |
|
Heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
Gal-3 is an independent predictor of mortality and HF post-MI.
|
31072572 |
2019 |
|
Heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
Galectin-3 (Gal-3) is implicated in the pathogenesis of heart failure and is also influenced by ageing.
|
31392851 |
2019 |
|
Heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
Galectin-3 (Gal-3) and soluble suppression of tumorigenicity 2 (ST2) are very interesting biomarkers for heart failure and myocardial fibrosis.
|
31622239 |
2020 |
|
Heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
Galectin-3 was not associated with either HF with reduced EF or HF with preserved EF.
|
31645163 |
2019 |
|
Heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
Galectin-3 (Gal-3) is involved in fibrosis and heart failure.
|
31772609 |
2019 |
|
Heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
A positive correlation between NGAL and galectin-3 in HF patients was found, revealing a potential association between renal injury and myocardial fibrosis and remodeling in HF.
|
30511581 |
2018 |